Briacell Therapeutics Stock Forward View - Triple Exponential Smoothing
| BCT Stock | 5.77 0.04 0.70% |
Momentum
Sell Peaked
Oversold | Overbought |
EPS Estimate Current Year -11.45 | EPS Estimate Next Year -3.40 | Wall Street Target Price 20 | EPS Estimate Current Quarter -3.28 |
The hype-based view summarizes Briacell Therapeutics' price response to recent headlines and peer coverage.
The Triple Exponential Smoothing forecasted value of Briacell Therapeutics Corp on the next trading day is expected to be 5.70 with a mean absolute deviation of 0.57 and the sum of the absolute errors of 33.87.Briacell Therapeutics after-hype prediction price | C$ 5.77 |
This sentiment summary adds context across forecasting, technical, analyst, and earnings perspectives for the stock.
Briacell |
Briacell Therapeutics Additional Predictive Modules
Forecasting Briacell Therapeutics's price movement relies on structured analysis of indicator behavior, momentum signatures, and historical volatility patterns. Model confidence should be calibrated against recent prediction accuracy for Briacell, not just historical fit.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Triple Exponential Smoothing Price Forecast For the 18th of March 2026
Given 90 days horizon, the Triple Exponential Smoothing forecasted value of Briacell Therapeutics Corp on the next trading day is expected to be 5.70 with a mean absolute deviation of 0.57 , mean absolute percentage error of 1.62 , and the sum of the absolute errors of 33.87 .Please note that although there have been many attempts to predict Briacell Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Briacell Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Stock Forecast Pattern
| Backtest Briacell Therapeutics | Briacell Therapeutics Price Prediction | Research Analysis |
Forecasted Value
Forecasting Briacell Therapeutics Corp for the next session involves measuring the model's historical ability to define credible downside and upside scenarios. The projected forecast band currently runs from roughly 0.06 on the downside to about 16.33 on the upside.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Triple Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of Briacell Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Briacell Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | Huge |
| Bias | Arithmetic mean of the errors | 0.1336 |
| MAD | Mean absolute deviation | 0.5741 |
| MAPE | Mean absolute percentage error | 0.0747 |
| SAE | Sum of the absolute errors | 33.8696 |
The degree to which Briacell Therapeutics' exhibits mean reversion depends on how efficiently the market prices new information. In highly covered equities, the mean reversion window tends to be shorter.
After-Hype Price Density Analysis
The after-hype price distribution for Briacell Therapeutics helps investors understand how much of Briacell Therapeutics' predicted return comes from the central scenario versus tail outcomes. Strategies that rely on tail events for Briacell Therapeutics are inherently more speculative.
Next price density |
| Expected price to next headline |
Estimiated After-Hype Price Volatility
Historical news patterns for Briacell Therapeutics reveal how the market has historically digested different types of information about Briacell Therapeutics' business and market environment. Briacell Therapeutics' after-hype downside and upside margins for the prediction period are 0.29 and 16.32, respectively. The model extrapolates these patterns to estimate likely price boundaries following the next significant.
Current Value
Macroaxis estimates the after-hype price of Briacell Therapeutics Corp across a 3 months horizon to evaluate where the instrument could settle once headline distortion subsides. Used correctly, the estimate adds context around potential normalization rather than promising a specific realized outcome.
Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Briacell Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Briacell Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Briacell Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.55 | 10.63 | 0.12 | 0.00 | 5 Events | 1 Events | In 5 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
5.77 | 5.77 | 0.00 |
|
Hype Timeline
Briacell Therapeutics is currently traded for 5.77on Toronto Exchange of Canada. The company has historical hype elasticity of 0.12, and average elasticity to hype of competition of 0.0. Briacell is anticipated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is anticipated to be very small, whereas the daily expected return is currently at -0.55%. %. The volatility of related hype on Briacell Therapeutics is about 141733.33%, with the expected price after the next announcement by competition of 5.77. The book value of the company was currently reported as 5.89. The company recorded a loss per share of 46.07. Briacell Therapeutics had its last dividend issued on the 2nd of January 2020. The company completed a 1:10 stock split on 25th of August 2025. Assuming the 90-day trading horizon the next anticipated press release will be in 5 days. Historical Fundamental Analysis of Briacell Therapeutics provides a cross-check on projections for Briacell Therapeutics. The historical view provides additional context.Related Hype Analysis
Peer hype analysis helps investors build a more complete picture of Briacell Therapeutics' competitive environment by quantifying the market's sensitivity to news across all major players in Briacell Therapeutics's sector.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| RVX | Resverlogix Corp | 0.00 | 5 per month | 3.62 | 0.03 | 10.00 | -9.09 | 20.20 | |
| PINK | Perimeter Medical Imaging | -0.03 | 2 per month | 7.24 | 0.16 | 20.00 | -14.29 | 108.27 | |
| HEM | Hemostemix | 0.00 | 4 per month | 4.40 | 0.02 | 6.25 | -9.09 | 40.52 | |
| MBX | Microbix Biosystems | 0.00 | 8 per month | 2.92 | 0.04 | 4.55 | -4.35 | 17.04 |
Other Forecasting Options for Briacell Therapeutics
The price trajectory of Briacell is the primary concern for any investor assessing it as an opportunity. Briacell Stock price charts are filled with noise that can easily mislead uninformed investment decisions.Briacell Therapeutics Related Equities
The following equities are related to Briacell Therapeutics within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Briacell Therapeutics against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Briacell Therapeutics Market Strength Events
Understanding the market strength of Briacell Therapeutics stock enables investors to assess the security's momentum and responsiveness to broader market forces. These indicators are essential tools for timing trades in Briacell Therapeutics Corp with greater precision.
Briacell Therapeutics Risk Indicators
Reviewing Briacell Therapeutics' basic risk indicators is essential for investors who want to forecast its price and manage their investment risk effectively. This analysis helps identify the amount of risk involved in holding Briacell Therapeutics' and informs decisions about hedging and position.
| Mean Deviation | 5.45 | |||
| Standard Deviation | 10.27 | |||
| Variance | 105.54 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Briacell Therapeutics
Coverage intensity for Briacell Therapeutics Corp matters because narrative visibility can influence sentiment, participation, and volatility around the name. The practical risk is that faster visibility can increase both interest and skepticism at the same time.
Other Macroaxis Stories
Macroaxis publishes story content for a diverse readership that includes finance students, independent investors, money managers, and market-focused operating teams. What connects that audience is a focus on building stronger portfolios through better research, risk awareness, and comparative analysis.
Story Categories
Currently Trending Categories
Briacell Therapeutics Short Properties
Short sentiment tied to Briacell Therapeutics Corp matters because heavier bearish pressure can change how quickly future price expectations become unstable. A disciplined short-interest review can make timing decisions more informed under rising skepticism.
| Common Stock Shares Outstanding | 423.1 K | |
| Cash And Short Term Investments | 17.9 M |
More Resources for Briacell Stock Analysis
Reviewing Briacell Therapeutics commonly begins with financial statements and performance trends. Ratios and trend metrics help frame Briacell Therapeutics' operating context across reporting periods. Key reports that frame Briacell Therapeutics Corp Stock are listed below:Historical Fundamental Analysis of Briacell Therapeutics provides a cross-check on projections for Briacell Therapeutics. The historical view provides additional context. Briacell Therapeutics currently shows ROE of -1.79%, market cap of 41.84 Million. Briacell Therapeutics data on this page supports broader research - the resources below add portfolio-level context. A thorough Briacell Therapeutics review pairs this page with the quantitative and comparative resources listed below. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.